Cantor Fitzgerald lowered the firm’s price target on Harrow (HROW) to $91 from $94 and keeps an Overweight rating on the shares. The firm moderated Iheezo and Vevye revenue to align with guidance.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HROW:
- Harrow price target lowered to $62 from $66 at Ladenburg
- Harrow price target raised to $70 from $69 at H.C. Wainwright
- Harrow announces U.S. FDA cleared an IND application for trial of Triesence
- Closing Bell Movers: MongoDB down over 20% after soft Q1 guidance
- Harrow Health Posts Record 2025 Results, Sets 2026 Outlook